Arch Immunol Ther Exp (Warsz) 2018 Jan 17. Epub 2018 Jan 17.
Department of Immunology, Transplantology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
The idea of using the effector immune cells to specifically fight cancer has recently evolved into an exciting concept of adoptive cell therapies. Indeed, genetically engineered T cells expressing on their surface recombinant, cancer-targeted receptors have been shown to induce promising response in oncological patients. However, in addition to exogenous expression of such receptors, there is also a need for disruption of certain genes in the immune cells to achieve more potent disease-targeted actions, to produce universal chimeric antigen receptor-based therapies or to study the signaling pathways in detail. Read More